Headlines

Pfizer sees all-time high for 2022 revenues; but declining COVID-19 products market will hit 2023 sales

Pfizer expects to see a 64% drop in Comirnaty revenues this year, which will hit its 2023 revenue guidance.

New US CDMO launched to address viral vector supply bottleneck

Vector BioMed, a CDMO specializing in the manufacture of lentiviral vectors, launched this week; its first financing round was led by Viking Global Investors and Casdin Capital.

Say hello to Biopharma Reporter's new look!

Say hello to our new look!

BioPharma-Reporter is revealing a brand-new design, including a new logo and website with improved usability.

BioNTech completes first in-house plasmid DNA manufacturing facility

mRNA pioneer BioNTech has completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany.

© GettyImages/John M Lund Photography Inc

Prothena: Trial data underscores the potential of antibody in treating Alzheimer’s disease

Biotechnology company, Prothena, has announced positive topline P1 SAD study results for PRX005, an investigational tri-epitopic antibody for the treatment of Alzheimer’s disease.